Fulgent Genetics, Inc.
FLGT
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancerā¦ read more
Healthcare
Diagnostics & Research
9 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$26.01
Price-0.99%
-$0.26
1Y
Price
Market Cap
$798.388m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-0.1%
EBITDA Margin-7.9%
Net Profit Margin+6.0%
Free Cash Flow Margin-0.1%
EBITDA Margin-7.9%
Net Profit Margin+6.0%
Free Cash Flow MarginRevenue
$315.549m
+11.3%
1y CAGR-14.6%
3y CAGR-20.4%
5y CAGREarnings
-$42.983m
-0.6%
1y CAGR-47.7%
3y CAGR-53.7%
5y CAGREPS
-$1.38
+2.1%
1y CAGR-48.2%
3y CAGR-54.0%
5y CAGRBook Value
$1.121b
$1.215b
Assets$93.806m
Liabilities$7.543m
DebtDebt to Assets
0.6%
-0.2x
Debt to EBITDAFree Cash Flow
-$19.849m
-3.1%
1y CAGR-200.8%
3y CAGR-164.2%
5y CAGRNo items found.
Press Releases
Statements and updates from the company